Compare Cadila Healthcare with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs AJANTA PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE AJANTA PHARMA CADILA HEALTHCARE/
AJANTA PHARMA
 
P/E (TTM) x 14.9 23.1 64.6% View Chart
P/BV x 2.9 4.1 71.5% View Chart
Dividend Yield % 1.4 0.9 162.5%  

Financials

 CADILA HEALTHCARE   AJANTA PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
AJANTA PHARMA
Mar-19
CADILA HEALTHCARE/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs5581,422 39.2%   
Low Rs362898 40.3%   
Sales per share (Unadj.) Rs116.3233.5 49.8%  
Earnings per share (Unadj.) Rs17.944.0 40.6%  
Cash flow per share (Unadj.) Rs23.152.2 44.4%  
Dividends per share (Unadj.) Rs3.509.00 38.9%  
Dividend yield (eoy) %0.80.8 98.1%  
Book value per share (Unadj.) Rs85.4255.1 33.5%  
Shares outstanding (eoy) m1,023.7488.02 1,163.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.05.0 79.6%   
Avg P/E ratio x25.726.4 97.5%  
P/CF ratio (eoy) x19.922.2 89.4%  
Price / Book Value ratio x5.44.5 118.4%  
Dividend payout %19.620.5 95.7%   
Avg Mkt Cap Rs m470,664102,081 461.1%   
No. of employees `00011.86.8 173.8%   
Total wages/salary Rs m18,5454,307 430.6%   
Avg. sales/employee Rs Th10,072.73,022.6 333.2%   
Avg. wages/employee Rs Th1,569.1633.4 247.7%   
Avg. net profit/employee Rs Th1,547.7569.1 272.0%   
INCOME DATA
Net Sales Rs m119,04920,554 579.2%  
Other income Rs m1,132211 537.0%   
Total revenues Rs m120,18120,765 578.8%   
Gross profit Rs m28,4755,664 502.7%  
Depreciation Rs m5,388721 747.5%   
Interest Rs m91112 7,853.4%   
Profit before tax Rs m23,3085,143 453.2%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6441,273 443.4%   
Profit after tax Rs m18,2923,870 472.7%  
Gross profit margin %23.927.6 86.8%  
Effective tax rate %24.224.8 97.8%   
Net profit margin %15.418.8 81.6%  
BALANCE SHEET DATA
Current assets Rs m82,00511,812 694.2%   
Current liabilities Rs m60,7203,776 1,607.9%   
Net working cap to sales %17.939.1 45.7%  
Current ratio x1.43.1 43.2%  
Inventory Days Days7377 94.5%  
Debtors Days Days9882 120.5%  
Net fixed assets Rs m83,70314,398 581.3%   
Share capital Rs m1,024175 583.8%   
"Free" reserves Rs m86,42122,277 387.9%   
Net worth Rs m87,44522,452 389.5%   
Long term debt Rs m25,5517 387,136.4%   
Total assets Rs m180,65326,962 670.0%  
Interest coverage x26.6444.3 6.0%   
Debt to equity ratio x0.30 99,399.9%  
Sales to assets ratio x0.70.8 86.4%   
Return on assets %10.614.4 73.8%  
Return on equity %20.917.2 121.4%  
Return on capital %22.023.0 95.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68310,682 399.6%   
Fx outflow Rs m11,2422,102 534.8%   
Net fx Rs m31,4418,580 366.5%   
CASH FLOW
From Operations Rs m9,1933,748 245.3%  
From Investments Rs m-9,737-2,228 437.0%  
From Financial Activity Rs m515-1,475 -34.9%  
Net Cashflow Rs m-2945 -64.2%  

Share Holding

Indian Promoters % 74.8 73.8 101.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 1.6 535.5%  
FIIs % 5.9 7.6 77.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.0 64.7%  
Shareholders   44,069 20,968 210.2%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Climbs 975 Points Up; FMCG Stocks Fuel the Rally(09:30 am)

Asian share markets started higher on Monday on hopes of an interim Sino-US tariff deal after the two countries described their talks as "productive" and "constructive".

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 23, 2019 12:23 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS